Agomelatine
Valdoxan (agomelatine) is a small molecule pharmaceutical. Agomelatine was first approved as Valdoxan on 2009-02-19. It has been approved in Europe to treat major depressive disorder. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B. In addition, it is known to target 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, and 5-hydroxytryptamine receptor 2B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 10 | 4 | 5 | 19 |
| Depression | D003863 | — | F33.9 | — | — | 9 | 5 | 4 | 18 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 9 | 3 | 4 | 16 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | 2 | — | 3 |
| Recurrence | D012008 | — | — | — | — | — | 1 | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
| Chronobiology disorders | D021081 | — | — | — | — | — | 1 | — | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | 1 | — | 1 |
| Parasomnias | D020447 | — | G47.5 | — | — | — | 1 | — | 1 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | 1 | — | — | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | — | 1 |
| Compulsive personality disorder | D003193 | — | F60.5 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | — | — | 1 | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 1 | 1 |
| Magnetic resonance imaging | D008279 | — | — | — | — | — | — | 1 | 1 |
| Electroconvulsive therapy | D004565 | — | — | — | — | — | — | 1 | 1 |
| Polymerase chain reaction | D016133 | OBI_0000415 | — | — | — | — | — | 1 | 1 |
| Genetic polymorphism | D011110 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Agomelatine |
| INN | agomelatine |
| Description | Thymanax, Valdoxan (agomelatine) is a small molecule pharmaceutical. Agomelatine was first approved as Thymanax on 2009-02-19. It has been approved in Europe to treat major affective disorder 2. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B. In addition, it is known to target 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C, and 5-hydroxytryptamine receptor 2A. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc2cccc(CCNC(C)=O)c2c1 |
Identifiers
| PDB | — |
| CAS-ID | 138112-76-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL10878 |
| ChEBI ID | — |
| PubChem CID | 82148 |
| DrugBank | DB06594 |
| UNII ID | 137R1N49AD (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,320 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,064 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use